These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38892423)

  • 1. The Neuroimmune Axis and Its Therapeutic Potential for Primary Liver Cancer.
    Mandal SK; Yadav P; Sheth RA
    Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive study of the interplay between immunological and metabolic factors in hepatic steatosis.
    Banerjee A; Das D; Mukherjee S; Maji BK
    Int Immunopharmacol; 2024 May; 133():112091. PubMed ID: 38657500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease promotes hepatocellular carcinoma through direct and indirect effects on hepatocytes.
    Ma C; Zhang Q; Greten TF
    FEBS J; 2018 Feb; 285(4):752-762. PubMed ID: 28857485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.
    Ma C; Kesarwala AH; Eggert T; Medina-Echeverz J; Kleiner DE; Jin P; Stroncek DF; Terabe M; Kapoor V; ElGindi M; Han M; Thornton AM; Zhang H; Egger M; Luo J; Felsher DW; McVicar DW; Weber A; Heikenwalder M; Greten TF
    Nature; 2016 Mar; 531(7593):253-7. PubMed ID: 26934227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
    Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
    BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophages in metabolic associated fatty liver disease.
    Alharthi J; Latchoumanin O; George J; Eslam M
    World J Gastroenterol; 2020 Apr; 26(16):1861-1878. PubMed ID: 32390698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.
    Chen S; Guo H; Xie M; Zhou C; Zheng M
    Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease.
    Fontes A; Alemany-Pagès M; Oliveira PJ; Ramalho-Santos J; Zischka H; Azul AM
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
    Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAFLD-related HCC.
    Banini BA; Sanyal AJ
    Adv Cancer Res; 2021; 149():143-169. PubMed ID: 33579423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
    Pfister D; Núñez NG; Pinyol R; Govaere O; Pinter M; Szydlowska M; Gupta R; Qiu M; Deczkowska A; Weiner A; Müller F; Sinha A; Friebel E; Engleitner T; Lenggenhager D; Moncsek A; Heide D; Stirm K; Kosla J; Kotsiliti E; Leone V; Dudek M; Yousuf S; Inverso D; Singh I; Teijeiro A; Castet F; Montironi C; Haber PK; Tiniakos D; Bedossa P; Cockell S; Younes R; Vacca M; Marra F; Schattenberg JM; Allison M; Bugianesi E; Ratziu V; Pressiani T; D'Alessio A; Personeni N; Rimassa L; Daly AK; Scheiner B; Pomej K; Kirstein MM; Vogel A; Peck-Radosavljevic M; Hucke F; Finkelmeier F; Waidmann O; Trojan J; Schulze K; Wege H; Koch S; Weinmann A; Bueter M; Rössler F; Siebenhüner A; De Dosso S; Mallm JP; Umansky V; Jugold M; Luedde T; Schietinger A; Schirmacher P; Emu B; Augustin HG; Billeter A; Müller-Stich B; Kikuchi H; Duda DG; Kütting F; Waldschmidt DT; Ebert MP; Rahbari N; Mei HE; Schulz AR; Ringelhan M; Malek N; Spahn S; Bitzer M; Ruiz de Galarreta M; Lujambio A; Dufour JF; Marron TU; Kaseb A; Kudo M; Huang YH; Djouder N; Wolter K; Zender L; Marche PN; Decaens T; Pinato DJ; Rad R; Mertens JC; Weber A; Unger K; Meissner F; Roth S; Jilkova ZM; Claassen M; Anstee QM; Amit I; Knolle P; Becher B; Llovet JM; Heikenwalder M
    Nature; 2021 Apr; 592(7854):450-456. PubMed ID: 33762733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome.
    Michelotti A; de Scordilli M; Palmero L; Guardascione M; Masala M; Roncato R; Foltran L; Ongaro E; Puglisi F
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response.
    Delaune V; Orci LA; Lacotte S; Peloso A; Schrenzel J; Lazarevic V; Toso C
    Expert Opin Biol Ther; 2018 Oct; 18(10):1061-1071. PubMed ID: 30173562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
    Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
    Front Immunol; 2020; 11():609900. PubMed ID: 33574818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma.
    Koo SY; Park EJ; Lee CW
    Exp Mol Med; 2020 Aug; 52(8):1209-1219. PubMed ID: 32770081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
    Dongiovanni P; Romeo S; Valenti L
    World J Gastroenterol; 2014 Sep; 20(36):12945-55. PubMed ID: 25278690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma.
    Behary J; Amorim N; Jiang XT; Raposo A; Gong L; McGovern E; Ibrahim R; Chu F; Stephens C; Jebeili H; Fragomeli V; Koay YC; Jackson M; O'Sullivan J; Weltman M; McCaughan G; El-Omar E; Zekry A
    Nat Commun; 2021 Jan; 12(1):187. PubMed ID: 33420074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Krizanac M; Mass Sanchez PB; Weiskirchen R; Asimakopoulos A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.